GIOMMONI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 2.535
EU - Europa 2.373
AS - Asia 1.563
SA - Sud America 135
Continente sconosciuto - Info sul continente non disponibili 66
AF - Africa 37
OC - Oceania 20
Totale 6.729
Nazione #
US - Stati Uniti d'America 2.465
IT - Italia 653
RU - Federazione Russa 582
PL - Polonia 577
CN - Cina 454
SG - Singapore 401
HK - Hong Kong 191
IE - Irlanda 142
VN - Vietnam 141
KR - Corea 128
BR - Brasile 104
FI - Finlandia 70
IN - India 65
SE - Svezia 64
FR - Francia 61
DE - Germania 58
CA - Canada 41
AT - Austria 40
GB - Regno Unito 39
BD - Bangladesh 38
JO - Giordania 38
ID - Indonesia 35
NL - Olanda 25
JP - Giappone 22
AU - Australia 20
CH - Svizzera 20
MX - Messico 18
ES - Italia 10
ZA - Sudafrica 10
IQ - Iraq 9
AR - Argentina 8
MA - Marocco 7
UA - Ucraina 7
NG - Nigeria 6
PK - Pakistan 6
VE - Venezuela 6
CL - Cile 5
MY - Malesia 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
CZ - Repubblica Ceca 4
EG - Egitto 4
UZ - Uzbekistan 4
AL - Albania 3
BE - Belgio 3
EC - Ecuador 3
LT - Lituania 3
PH - Filippine 3
TR - Turchia 3
CI - Costa d'Avorio 2
ET - Etiopia 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TW - Taiwan 2
AD - Andorra 1
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GP - Guadalupe 1
GT - Guatemala 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
MD - Moldavia 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SN - Senegal 1
TG - Togo 1
TT - Trinidad e Tobago 1
Totale 6.663
Città #
Warsaw 576
Santa Clara 520
Ashburn 440
Singapore 274
Hong Kong 171
Hefei 151
San Jose 151
Dublin 136
Seoul 128
Florence 95
Milan 90
Fairfield 88
Council Bluffs 76
Chandler 63
Beijing 54
Los Angeles 52
Seattle 47
Rome 41
Helsinki 40
New York 40
Vienna 39
Ho Chi Minh City 37
Woodbridge 37
Wilmington 35
Cambridge 34
Dallas 34
Houston 34
Munich 34
Buffalo 33
Lauterbourg 32
Jakarta 31
Hanoi 30
Moscow 29
Boston 24
Paris 24
Boardman 22
Lawrence 22
Shanghai 22
Altamura 21
Pune 20
Kent 19
Mumbai 19
Melbourne 18
Tokyo 18
Chicago 17
The Dalles 17
Bern 16
Dong Ket 16
Phoenix 16
Turku 16
Princeton 15
Toronto 14
London 13
Turin 12
Bengaluru 11
Naples 11
São Paulo 11
Atlanta 10
Orem 9
Ann Arbor 8
Brescia 8
Figino 8
Lappeenranta 8
Montesilvano Marina 8
Montreal 8
North Charleston 8
West Jordan 8
Amsterdam 7
Frankfurt am Main 7
Genoa 7
Johannesburg 7
Medford 7
Brasília 6
Bremen 6
Brooklyn 6
Dearborn 6
Haiphong 6
Redondo Beach 6
San Diego 6
San Francisco 6
Shenzhen 6
Tianjin 6
Abuja 5
Bari 5
Belo Horizonte 5
Catania 5
Charlotte 5
Cinisello Balsamo 5
Las Vegas 5
Mexico City 5
Mosier 5
Palermo 5
St Louis 5
Treviso 5
Washington 5
Amandola 4
Barnet 4
Biên Hòa 4
Bologna 4
Cagliari 4
Totale 4.349
Nome #
hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications 354
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: A phase II study 350
VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohort. 306
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 289
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 267
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 256
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 240
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 236
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 217
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 210
Update on gastric cancer treatments and gene therapies 210
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 208
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 207
Immune-related adverse events in oncological patients treated with immune checkpoint inhibitors 201
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 197
Somatostatin analogs in pregnant patients with neuroendocrine tumor 195
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 194
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients 192
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 192
Results of the observational prospective RealFLOT study 190
hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. 185
Systemic Sclerosis Association with Malignancy 183
Editorial: Redox Potential and Metabolic Behavior in Gastrointestinal Cancers 177
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 174
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors 173
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 169
Regorafenib also can cause osteonecrosis of the jaw 158
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine 139
Response 137
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 134
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 131
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations 99
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 97
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 62
Totale 6.729
Categoria #
all - tutte 20.553
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.553


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022105 0 0 0 3 4 1 4 17 11 8 26 31
2022/2023490 23 70 17 24 36 97 67 40 61 14 19 22
2023/2024445 8 29 33 17 30 73 26 80 11 42 46 50
2024/20251.828 48 161 103 271 456 253 41 115 80 59 105 136
2025/20262.495 300 325 278 226 255 74 258 127 153 158 86 255
2026/2027420 114 72 145 89 0 0 0 0 0 0 0 0
Totale 6.729